These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 7890372)
1. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Shahin R; Leef M; Eldridge J; Hudson M; Gilley R Infect Immun; 1995 Apr; 63(4):1195-200. PubMed ID: 7890372 [TBL] [Abstract][Full Text] [Related]
2. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Conway MA; Madrigal-Estebas L; McClean S; Brayden DJ; Mills KH Vaccine; 2001 Feb; 19(15-16):1940-50. PubMed ID: 11228364 [TBL] [Abstract][Full Text] [Related]
7. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens. Macdonald-Fyall J; Xing D; Corbel M; Baillie S; Parton R; Coote J Vaccine; 2004 Oct; 22(31-32):4270-81. PubMed ID: 15474718 [TBL] [Abstract][Full Text] [Related]
8. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Kimura A; Mountzouros KT; Relman DA; Falkow S; Cowell JL Infect Immun; 1990 Jan; 58(1):7-16. PubMed ID: 2294058 [TBL] [Abstract][Full Text] [Related]
9. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Allaoui-Attarki K; Pecquet S; Fattal E; Trollé S; Chachaty E; Couvreur P; Andremont A Infect Immun; 1997 Mar; 65(3):853-7. PubMed ID: 9038287 [TBL] [Abstract][Full Text] [Related]
10. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794 [TBL] [Abstract][Full Text] [Related]
11. Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Yan C; Rill WL; Malli R; Hewetson J; Naseem H; Tammariello R; Kende M Vaccine; 1996 Aug; 14(11):1031-8. PubMed ID: 8879098 [TBL] [Abstract][Full Text] [Related]
12. Protection against intranasal infection of mice with Bordetella pertussis. Robinson A; Ashworth LA; Baskerville A; Irons LI Dev Biol Stand; 1985; 61():165-72. PubMed ID: 2872102 [TBL] [Abstract][Full Text] [Related]
13. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA. Roberts M; Cropley I; Chatfield S; Dougan G Vaccine; 1993; 11(8):866-72. PubMed ID: 8356847 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. Orr B; Douce G; Baillie S; Parton R; Coote J Vaccine; 2007 Jan; 25(1):64-71. PubMed ID: 16916566 [TBL] [Abstract][Full Text] [Related]
15. PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model. Li P; Asokanathan C; Liu F; Khaing KK; Kmiec D; Wei X; Song B; Xing D; Kong D Int J Pharm; 2016 Nov; 513(1-2):183-190. PubMed ID: 27586408 [TBL] [Abstract][Full Text] [Related]
16. Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin. Cahill ES; O'Hagan DT; Illum L; Redhead K FEMS Microbiol Lett; 1993 Mar; 107(2-3):211-6. PubMed ID: 8472903 [TBL] [Abstract][Full Text] [Related]
17. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection. Denoël P; Poolman J; Carletti G; Veitch K Vaccine; 2002 Jun; 20(19-20):2551-5. PubMed ID: 12057612 [TBL] [Abstract][Full Text] [Related]
18. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model. Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625 [TBL] [Abstract][Full Text] [Related]
20. Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein. Carbonetti NH; Artamonova GV; Andreasen C; Dudley E; Mays RM; Worthington ZE Infect Immun; 2004 Jun; 72(6):3350-8. PubMed ID: 15155640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]